Candida Labs

And how to conquer.

Peep This. P. David Rogers Peter Pappas David Perlin William Hope

David Perlin Ph.D.

Dr. Perlin has helped establish PHRI as a leading center for research in infectious diseases with an emphasis on clinical research involving tuberculosis, HIV and other viral, bacterial and fungal pathogens.

Dr. Perlin lectures on resistant and hospital acquired infections, and regularly comments in mainstream media outlets, such as the New York Times

Focus of Study The Perlin lab is interested in mechanisms of

antifungal drug resistance, rapid detection of bloodstream and respiratory pathogens in high-risk patients, and the application of small animal models for respiratory pathogens.

Thus, the focus of the Perlin lab is not just Candida but rather resistance and detection on a larger scale encompassing various types of fungi and respiratory viruses and develop methods on solving those problems.

Other Studies They are also studying the mechanism of

triazole resistance in Aspergillus fumigatus. They study nucleic acid PCR- and NASBA-

based molecular beacon platforms for rapid identification of bacterial and fungal pathogens in KPC, MRSA, VRE, C. difficile, Candida spp. and Aspergillus spp.

Developing panels for the rapid detection of some common respiratory viruses.

Publications 4 publications on PubMed during this

year, all of which are on Candida. Around 40 different publications in the

past few years

Sponsors Supported by grants from the NIH, Bill and

Melinda Gates Foundation, Pharma and biotech sectors

Committees He is on the editorial board of several

scientific journals and participates in NIH reviews of grants

the Board of Directors of the Aaron Diamond AIDS Research Center

Scientific/Medical Advisory Boards for Merck, Pfizer, Astellas, ElusysPharmaceuticals, Inc., Myconostica, LTD, BioDelivery Sciences Int’l., and PinnacleCare.

Member of the New York City Department of Health Advisory Panel on Bioterrorism and Emerging Infections

Research Group Executive Director and President at Public

Health Research Institute Center at the UMDNJ - New Jersey Medical School

Patents: He has a fewNumber Description

20100075302 Assays for Resistance to Echinocandin-Class Drugs - Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1Also, primers, probes and reagent kits for performing such assays.

20100221710 Assays For Fungal Infection - Methods and kits are described for testing for the presence or absence of any fungus in a sample.

20110091872 Detecting Triazole Resistance In Aspergillus -. The methods comprise evaluating the sample for the presence of a gene encoding a mutant AzRF1 transcription factor, or the level of the transcription factor, to determine whether a fungus is triazole-resistant. Primers, probes and kits also are provided.

Peter Pappas M.D.  Dr. Peter G. Pappas M.D. is a Professor of

Medicine in the Division of Infectious Diseases, Department of Medicine at the University of Alabama in Birmingham.

Dr. Pappas graduated from University of Alabama at Birmingham School of Medicine and completed his residency (internal medicine) and fellowship (infectious disease) at the University of Washington.

Focus of Study Pappas has a focus on infections in

immunocompromised hosts, with a specific focus on the invasive mycoses.

His main areas of research interest have included the development of new therapies for fungal infections and understanding the epidemiology of candidiasis, the endemic mycoses, and cryptococcosis.

Other Studies He has led a number of randomized clinical

trials in cryptococcosis, aspergillosis, sporotrichosis, blastomycosis, and histoplasmosis.

He is also interested in transplant associated infections including the invasive mycoses.

Publications Dr. Pappas has published more than 130

peer-reviewed manuscripts, over 50 chapters, over 130 abstracts for scientific meetings, and has co-authored 6 books

He has had 11 publications this year including 4 on Candida

Sponsors The University of Alabama at Birmingham

Division of Infectious Diseases’ research is funded by the National Institutes of Health (NIH)

The Mycoses Study Group is funded by the NIAID (National Institute of Allergy and Infectious Diseases)

Committees Member of Clinical Advisory Board of T2

Biosystems, Inc Principal Investigator for the MSG, a

clinical trials group that performs international multicenter trials, creates treatment guidelines for invasive mycoses, and describes the evolving epidemiology of fungal infections.

Committees cont.

Principal Investigator of the Organ Transplant Infection Detection and Prevention Program, a collaborative multicenter group funded by CDC to explore the risk factors and epidemiology of transplant associated infections.

He is also the PI of a national network of transplant centers, TRANSNET, in conjunction with CDC. TRANSNET provides important epidemiologic and treatment information concerning transplant recipients who develop proven and probable invasive fungal infections.

Affiliations American College of Physicians (fellow) American Society for Microbiology Infectious Diseases Society of America

(member) American Federation of Clinical

Research Southern Society of Clinical

Investigation

Patents

None found

P. David Rogers Pharm.D., PhD

P. David Rogers is a leading researcher in clinical pharmacy and medical mycology

Named First Tennessee Chair in 2006.

Dr. Rogers is Associate Dean for Translational Research for the College of Pharmacy

Professor and Vice Chair for Research for the Department of Clinical Pharmacy at the University of Tennessee College of Pharmacy.

Focus of Study The interests of Dr. David Rogers’ lab

revolve around three areas central to the management of infections due to C. albicans:

1) the molecular basis for the mechanism of specific antifungal agents. More specifically some Azole antifungals.

2) molecular mechanisms of antifungal resistance

3) the role of the innate immune response in the interaction between C. albicans and the host.

Other Studies Many of his recent studies are generally

around Candida. He doesn’t seem to have many recent publications that are unrelated.

His current work focuses on the elucidation of the molecular basis of antifungal resistance and tolerance in the pathogenic fungi Candida albicans and Candida glabrata which seems to be very similar to what the Perlin lab seems to be working on.

Publications P. David Rogers has authored more than

60 publications and published over 100 scientific abstracts.

Many of them are about Candida too.

Sponsors His studies are supported through grants

from associations, industry, and the National Institutes of Health.

Committees Dr. Rogers is : an elected Fellow of the American College of

Clinical Pharmacy member of the American Society for

Microbiology the Society of Infectious Diseases

Pharmacists, the Infectious Diseases Society of America He serves as a reviewer for multiple peer

reviewed journals and funding agencies and is a member of several editorial boards

Research Group Currently, the research is being at what

seems to be the College of Pharmacy at the University of Tennessee Health Science Center which seems fairly similar to what we are doing here.

Either that, or the work is coming from the Children's Foundation Research Center in Tennessee.

Patents

None Found

William Hope MBBS, PhD, FRCPA, FRACP

William Hope is an Infectious Diseases Physician who studies antimicrobial pharmacokinetics and pharmacodynamics.

NIHR Clinician Scientist, Clinical Senior Lecturer and Honorary Consultant in Infectious Diseases

TB lead for University Hospital South Manchester and provide infectious diseases support for solid organ transplant recipients

Focus of Study His work focuses mostly on animicrobial

pharmacokinetic-pharmacodynamic modeling techniques like PK and Monte Carlo simulation.

Techniques are applied to diseases that are difficult to study and to special populations.

He is interested in the individualization of antimicrobial therapy to achieve drug exposure targets that maximize the probability of a successful therapeutic outcome.

Other Studies Other antifungal work

unrelated to Candida- Invasive aspergillosis- Cryptococcal meningitis Bacterial pneumonia

Publications Hope and his research group have

published 10 studies in 2011 with 4 relating to Candida infections.

Sponsors His work funded by the Medical Research

Council and the National Institute of Health Research. (UK)

He also has a range of industrial collaborations.

Committees/Affiliations Fellow of the Royal College of Pathologists

of Australasia Fellow of the Royal Australasian College of

Physicians National Institute of Health Research

Senior Lecturer in Infectious Diseases Member of the steering committee for

antifungal agents for the European Committee of Antimicrobial Susceptibility Testing.

Research Group Collaborators/Staff: Professor David Denning

(The University of Manchester), Dr Peter Warn (The University of Manchester), Professor George Drusano (Ordway Research Institute), Professor Roger Jelliffe (University of Southern California), Professor Thomas Harrison (St George's London), Dr John Perfect (Duke, USA), Daniel Benjamin (Duke, USA).

Patents

None found.

ContactIn case you would like to stalk them some more… P. David Rogers

847 Monroe Ave. Suite 226Memphis, TN 38163Phone: (901) 448-6036Fax: (901) 448-7053

Peter Pappas University of Alabama at Birmingham

1900 University Boulevard 229 Tinsley Harrison Tower Birmingham, Alabama 35294-0006 Phone: (205) 934-5191; Fax: (205) 934-5155 E-mail: pappas@uab.edu

David PerlinPublic Health Research Institute CenterUMDNJ - New Jersey Medical School225 Warren StreetNewark, New Jersey 07103Phone: (973) 854-3200e-mail: perlinds@umdnj.edu

William HopeEmail: william.hope@manchester.ac.ukTelephone: +44 (0)161 275 3918Fax: +44 (0)161 275 5656Room 1.800, Stopford Building, The University of Manchester, Manchester, M13 9PT

In case you would like to stalk them some more… P. David Rogers

847 Monroe Ave. Suite 226Memphis, TN 38163Phone: (901) 448-6036Fax: (901) 448-7053

Peter Pappas University of Alabama at Birmingham

1900 University Boulevard 229 Tinsley Harrison Tower Birmingham, Alabama 35294-0006 Phone: (205) 934-5191; Fax: (205) 934-5155 E-mail: pappas@uab.edu

David PerlinPublic Health Research Institute CenterUMDNJ - New Jersey Medical School225 Warren StreetNewark, New Jersey 07103Phone: (973) 854-3200e-mail: perlinds@umdnj.edu

William HopeEmail: william.hope@manchester.ac.ukTelephone: +44 (0)161 275 3918Fax: +44 (0)161 275 5656Room 1.800, Stopford Building, The University of Manchester, Manchester, M13 9PT

Contact